Lord, Abbett & Co
XENE icon

Lord, Abbett & Co’s Xenon Pharmaceuticals XENE Stock Holding History

Lord, Abbett & Co’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-87,981
Closed -$2.95M – 595
2025
Q1 		$2.95M Sell
87,981
-106,990
-55% -$4.06M 0.01% 496
2024
Q4 		$7.64M Buy
194,971
+20,986
+12% +$868K 0.02% 421
2024
Q3 		$6.85M Sell
173,985
-16,048
-8% -$647K 0.02% 444
2024
Q2 		$7.41M Sell
190,033
-705,163
-79% -$28.2M 0.02% 420
2024
Q1 		$38.5M Buy
895,196
+177,224
+25% +$8.15M 0.12% 220
2023
Q4 		$33.1M Sell
717,972
-431,196
-38% -$15.2M 0.12% 239
2023
Q3 		$39.3M Sell
1,149,168
-809,372
-41% -$30.3M 0.15% 202
2023
Q2 		$75.4M Buy
1,958,540
+175,929
+10% +$6.99M 0.26% 117
2023
Q1 		$63.8M Sell
1,782,611
-341,398
-16% -$12.6M 0.23% 141
2022
Q4 		$83.7M Buy
2,124,009
+210,148
+11% +$7.65M 0.3% 86
2022
Q3 		$69.1M Buy
1,913,861
+56,265
+3% +$2.02M 0.25% 105
2022
Q2 		$56.5M Buy
1,857,596
+66,853
+4% +$2.02M 0.2% 145
2022
Q1 		$54.7M Sell
1,790,743
-4,337
-0.2% -$130K 0.15% 199
2021
Q4 		$56.1M Buy
1,795,080
+1,416,722
+374% +$42.3M 0.13% 237
2021
Q3 		$5.78M Sell
378,358
-6,367
-2% -$111K 0.01% 581
2021
Q2 		$7.16M Sell
384,725
-33,825
-8% -$623K 0.02% 579
2021
Q1 		$7.49M Buy
+418,550
New +$7.09M 0.02% 562

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co's XENE Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 87,981 shares — an estimated $2.95M sold.

Lord, Abbett & Co first reported a position in XENE in Q1 2021 and held it in 17 quarters. The position peaked at $83.7M in Q4 2022. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Lord, Abbett & Co reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 87,981 Xenon Pharmaceuticals shares in Q2 2025, an estimated $2.95M.
  • Lord, Abbett & Co first reported a position in Xenon Pharmaceuticals in Q1 2021 and held it in 17 quarters.
  • Lord, Abbett & Co's Xenon Pharmaceuticals position peaked at $83.7M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.